Last Friday, the "Mad Money" host did not recommend the stock Globalstar. This is a satellite phone company that is lobbying the Federal Communications Commission (FCC) for permission to use their electromagnetic spectrum to create a proprietary Wi-Fi service.
While Cramer initially did recommend this stock in July, he changed his opinion after hedge fund Kerrisdale Capital's decision to short the stock, claiming that it was headed to $0. It also attempted to block the FCC ruling in favor of Globalstar. Since that time, the stock has plummeted 11 percent in six months.
That is why the "Mad Money" host welcomed founder and CEO of Globalstar, Jay Monroe, to share his view on the company for investors to make a final call on Globalstar.
"It is polarizing because of Kerrisdale. Prior to that I think people understood pretty well that the spectrum was needed throughout the country… to me, when people understood that, and they understood how it was going to be used, it was relatively speaking, smooth sailing. When Kerrisdale introduced a lot of negative chatter to the discussion, taking positions that were technically unsound but that were nonetheless, loud, we ended up in the situation that we are in," Monroe said.
According to Kerrisdale's experts, the issue of Wi-Fi traffic is not as important as Globalstar has made it sound. While Globalstar would like to create access points for low-powered Wi-Fi, how in the world would they pay for this?
"It is almost free. If you think about how a network like this gets built out, it's almost viral in nature. The partner that we would have … is going to have access to your house already or access to the street already. As a result, they will build the network out," added Monroe.
Read More Cramer: Globalstar CEO defends his controversial stock
On the flip side, a company like Allergan is now reaping the benefits of great management. So much, that they were able to create some waves in the market on Merger Monday. Good management trickles down to a good investment. That is why Jim Cramer knows that plenty of money can be made when there is a terrific CEO who insists on good value.
Sometimes that value is brought out by hard work. Sometimes by ingenuity, technology and inventiveness. Sometimes it is all of these things combined, plus strong bargaining power.
"With this $219 Actavis bid, Allergan's David Pyott has accomplished all of those things for shareholders," Cramer said.
On Monday Actavis announced it had agreed to pay $66 billion, or $219 a share, for Botox maker Allergan. This is a landmark price, considering it was just trading at $28 six years ago.
"It's been a fabulous run, and Pyott deserves wall of fame like plaudits for what he has done for his shareholders during his amazing tenure at Allergan," Cramer said.
Read MoreCramer tips hat to Allergan
As for the Lightning Round, Cramer continued to give his opinion to caller favorites wondering if they were turnaround stocks:
J.C. Penney: "We do not recommend J.C. Penney. We do not think it is going to be a great stock, we feel it is going to just muddle through. That's not what I want out of a retailer. I think Wal-Mart is going to do better."
Mobileye: "I do think that Mobileye could have a good quarter. But this is a stock that really had a remarkable ride, and there seems to be profit taking everywhere. I think the quarter is going to be fine."
Read MoreLightning Round: Wal-Mart is better than this